JP7682797B2 - クローディン６二重特異性抗体 - Google Patents

クローディン６二重特異性抗体 Download PDF

Info

Publication number
JP7682797B2
JP7682797B2 JP2021556493A JP2021556493A JP7682797B2 JP 7682797 B2 JP7682797 B2 JP 7682797B2 JP 2021556493 A JP2021556493 A JP 2021556493A JP 2021556493 A JP2021556493 A JP 2021556493A JP 7682797 B2 JP7682797 B2 JP 7682797B2
Authority
JP
Japan
Prior art keywords
seq
binding protein
amino acid
antigen binding
nos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021556493A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022525478A5 (https=
JP2022525478A (ja
JPWO2020191344A5 (https=
Inventor
コンクリン，ディラン
マクダーモット，マルティナ，エス．
オブライエン，ニール，エー．
パラッツォロ，マイケル，ジェイ．
スレイモン，デニス
エウウ，エリカ ボン
バウワーズ，ピーター
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of JP2022525478A publication Critical patent/JP2022525478A/ja
Publication of JP2022525478A5 publication Critical patent/JP2022525478A5/ja
Publication of JPWO2020191344A5 publication Critical patent/JPWO2020191344A5/ja
Priority to JP2025080864A priority Critical patent/JP2025122027A/ja
Application granted granted Critical
Publication of JP7682797B2 publication Critical patent/JP7682797B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021556493A 2019-03-20 2020-03-20 クローディン６二重特異性抗体 Active JP7682797B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025080864A JP2025122027A (ja) 2019-03-20 2025-05-14 クローディン６二重特異性抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962821399P 2019-03-20 2019-03-20
US62/821,399 2019-03-20
PCT/US2020/023986 WO2020191344A1 (en) 2019-03-20 2020-03-20 Claudin-6 bispecific antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025080864A Division JP2025122027A (ja) 2019-03-20 2025-05-14 クローディン６二重特異性抗体

Publications (4)

Publication Number Publication Date
JP2022525478A JP2022525478A (ja) 2022-05-16
JP2022525478A5 JP2022525478A5 (https=) 2023-03-29
JPWO2020191344A5 JPWO2020191344A5 (https=) 2023-03-29
JP7682797B2 true JP7682797B2 (ja) 2025-05-26

Family

ID=72521273

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021556493A Active JP7682797B2 (ja) 2019-03-20 2020-03-20 クローディン６二重特異性抗体
JP2025080864A Pending JP2025122027A (ja) 2019-03-20 2025-05-14 クローディン６二重特異性抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025080864A Pending JP2025122027A (ja) 2019-03-20 2025-05-14 クローディン６二重特異性抗体

Country Status (6)

Country Link
US (1) US20220177583A1 (https=)
EP (1) EP3941944A4 (https=)
JP (2) JP7682797B2 (https=)
CN (1) CN114206934A (https=)
CA (1) CA3134056A1 (https=)
WO (1) WO2020191344A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020241896A1 (en) 2019-03-20 2021-09-23 The Regents Of The University Of California Claudin-6 antibodies and drug conjugates
IL322315A (en) 2019-05-14 2025-09-01 Provention Bio Inc Methods and preparations for preventing type 1 diabetes
CR20220049A (es) 2019-07-10 2022-03-02 Chugai Pharmaceutical Co Ltd Moléculas de unión a claudina-6 y usos de las mismas
AU2021287998B2 (en) 2020-06-11 2026-03-12 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes
AU2021374036A1 (en) * 2020-11-06 2023-06-08 Amgen Inc. Polypeptide constructs selectively binding to cldn6 and cd3
CA3212530A1 (en) * 2021-03-05 2022-09-09 Shanghai GenBase Biotechnology Co., Ltd. Anti-cldn6 antibody and use thereof
JP2024511319A (ja) * 2021-03-09 2024-03-13 ゼンコア インコーポレイテッド Ｃｄ３及びｃｌｄｎ６に結合するヘテロ二量体抗体
KR20240004680A (ko) * 2021-05-07 2024-01-11 센티 바이오사이언시스, 인코포레이티드 키메라 수용체 및 이의 사용 방법
US12565529B2 (en) 2021-05-24 2026-03-03 Provention Bio, Inc. Methods for treating type 1 diabetes
AU2022311053A1 (en) * 2021-07-15 2023-12-14 BioNTech SE Agents encoding cldn6 and cd3 binding elements for treating cldn6-positive cancers
MX2023015028A (es) * 2021-09-01 2024-02-16 Biosceptre Aust Pty Ltd Nuevos aglutinantes del p2x7 disfuncional.
CA3230426A1 (en) * 2021-09-03 2023-03-09 Novarock Biotherapeutics, Ltd. Bispecific binding proteins that bind cd137 and a tumor associated antigen
JPWO2023053282A1 (https=) * 2021-09-29 2023-04-06
EP4704916A1 (en) * 2023-04-29 2026-03-11 Innovent Biologics (Suzhou) Co., Ltd. Modified antibodies, antibody fragments thereof, and antibody-drug conjugates
US12403202B2 (en) 2023-05-25 2025-09-02 The Regents Of The University Of California Dosage of claudin-6 conjugates for cancer treatment

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014516956A (ja) 2011-05-13 2014-07-17 ガニメド ファーマシューティカルズ アーゲー 癌の治療のための抗体
JP2016500059A (ja) 2012-11-13 2016-01-07 バイオエヌテック アーゲーＢｉｏＮＴｅｃｈ ＡＧ クローディンを発現するガン疾患を処置するための剤

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US581916A (en) 1897-05-04 Harvester
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
US4342776A (en) 1979-11-05 1982-08-03 Merck & Co., Inc. 4-Substituted-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase
US4399276A (en) 1981-01-09 1983-08-16 Kabushiki Kaisha Yakult Honsha 7-Substituted camptothecin derivatives
US4473692A (en) 1981-09-04 1984-09-25 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
JPS5839685A (ja) 1981-09-04 1983-03-08 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体及びその製造法
JPS58154582A (ja) 1982-03-10 1983-09-14 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体およびその製造法
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
ATE92499T1 (de) 1984-12-04 1993-08-15 Lilly Co Eli Tumorbehandlung bei saeugetieren.
US5223608A (en) 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US5004758A (en) 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
IL106992A (en) 1988-02-11 1994-06-24 Bristol Myers Squibb Co Acylhydrazone derivatives of anthracycline and methods for their preparation
NZ235329A (en) 1989-09-15 1992-01-29 Res Triangle Inst 20(s or rs)-camptothecin derivatives and pharmaceutical compositions
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US6407115B1 (en) 1991-01-16 2002-06-18 Daiichi Pharmaceutical Co., Ltd. Hexa-cyclic compound
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
ES2149768T3 (es) 1992-03-25 2000-11-16 Immunogen Inc Conjugados de agentes enlazantes de celulas derivados de cc-1065.
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
FR2707988B1 (fr) 1993-07-21 1995-10-13 Pf Medicament Nouveaux dérivés antimitotiques des alcaloïdes binaires du catharantus rosesus, leur procédé de préparation et les compositions pharmaceutiques les comprenant.
ATE234635T1 (de) 1995-12-22 2003-04-15 Bristol Myers Squibb Co Verzweigte hydrazongruppen enthaltende kuppler
EP1053752A1 (en) 1998-02-10 2000-11-22 Yoshitomi Pharmaceutical Industries, Ltd. Preparations with controlled release
CA2346866A1 (en) 1998-10-16 2000-04-27 The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services Combination therapy with vip antagonist
GB2344287A (en) 1998-12-03 2000-06-07 Ferring Bv Controlled release pharmaceutical formulation
ES2276708T3 (es) 1999-11-24 2007-07-01 Immunogen, Inc. Agentes citotoxicos que comprenden taxanos y su uso terapeutico.
WO2001058479A1 (en) 2000-02-08 2001-08-16 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
CA2467633C (en) 2001-12-03 2012-03-27 Abgenix, Inc. Antibody categorization based on binding characteristics
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
US6756397B2 (en) 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
SI1545613T1 (sl) 2002-07-31 2011-11-30 Seattle Genetics Inc Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni
CN100522955C (zh) 2002-08-02 2009-08-05 伊缪诺金公司 含有新型强效紫杉烷的细胞毒性剂及其治疗用途
JP2006500364A (ja) 2002-08-16 2006-01-05 イムノージェン インコーポレーテッド 高い反応性と溶解度を有する架橋剤および小分子薬物の標的化送達用コンジュゲートの調製におけるそれらの使用
DE60331455D1 (de) 2002-10-04 2010-04-08 Microchips Inc Medizinische vorrichtung zur gesteuerten arzneimittelverabreichung sowie herzüberwachung und/oder herzstimulation
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
NZ580700A (en) 2007-04-19 2012-01-12 Dong A Pharm Co Ltd A biodegradable microsphere composition suitable for the controlled release of glucose controlling peptide and formulation thereof
KR20200058590A (ko) 2008-04-30 2020-05-27 이뮤노젠 아이엔씨 가교제 및 그 용도
EP2276506A4 (en) 2008-04-30 2014-05-07 Immunogen Inc EFFICIENT CONJUGATES AND HYDROPHILIC BINDER
EP3912643B8 (en) 2009-02-13 2023-08-23 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
EP2404936A1 (en) * 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
DK2907824T3 (en) 2012-10-11 2018-07-23 Daiichi Sankyo Co Ltd ANTIBODY-drug conjugate
WO2014075697A1 (en) * 2012-11-13 2014-05-22 Biontech Ag Agents for treatment of claudin expressing cancer diseases
WO2017079165A1 (en) 2015-11-02 2017-05-11 Genentech, Inc. Methods of making fucosylated and afucosylated forms of a protein
IL273196B2 (en) * 2017-09-18 2024-11-01 Univ California Claudin6 antibodies and methods of treating cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014516956A (ja) 2011-05-13 2014-07-17 ガニメド ファーマシューティカルズ アーゲー 癌の治療のための抗体
JP2016500059A (ja) 2012-11-13 2016-01-07 バイオエヌテック アーゲーＢｉｏＮＴｅｃｈ ＡＧ クローディンを発現するガン疾患を処置するための剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ONCOIMMUNOLOGY，2016年，VOL.5, NO.3，e1091555 (12 pages)，doi.org/10.1080/2162402X.2015.1091555

Also Published As

Publication number Publication date
CN114206934A (zh) 2022-03-18
EP3941944A1 (en) 2022-01-26
JP2025122027A (ja) 2025-08-20
US20220177583A1 (en) 2022-06-09
WO2020191344A1 (en) 2020-09-24
JP2022525478A (ja) 2022-05-16
EP3941944A4 (en) 2022-11-30
CA3134056A1 (en) 2020-09-24

Similar Documents

Publication Publication Date Title
JP7682797B2 (ja) クローディン６二重特異性抗体
KR102777693B1 (ko) Claudin18 항체 및 암 치료 방법
JP7682798B2 (ja) クローディン６抗体及び薬物複合体
JP7599332B2 (ja) クローディン６抗体及びがんを治療するための方法
JP2025503402A (ja) Ｃｄｈ１７抗体及びがんを処置する方法
JPWO2023107558A5 (https=)
JP2024546106A (ja) Ｄｌｋ１抗体及びがんを処置する方法
HK40125763A (en) Claudin-6 antibodies and drug conjugates
HK40067893B (en) Claudin-6 antibodies and drug conjugates
HK40067893A (en) Claudin-6 antibodies and drug conjugates
JPWO2023107560A5 (https=)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230320

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230320

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240206

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20240402

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240402

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240806

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250212

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250415

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250514

R150 Certificate of patent or registration of utility model

Ref document number: 7682797

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150